CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Key findings

3.1.1.Top Investment Pockets
3.1.2.Top Player Positioning, 2018
3.1.3.Key forces shaping the Asia-Pacific oncology molecular diagnostics market

3.2.Market dynamics

3.2.1.Drivers

3.2.1.1.Rise in prevalence of various types of cancersW
3.2.1.2.Growth in funding by governmentsW
3.2.1.3.Growth in biomarker identification

3.2.2.Restraints

3.2.2.1.Lack of skilled professionals
3.2.2.2.Stringent regulatory requirements for product approvals

3.2.3.Opportunities

3.2.3.1.Advancements in genomics and proteomics

3.3.Regulatory guidelines for molecular diagnostics
3.4.Recommended guidelines for oncology molecular diagnostics tests
3.5.Insights on clinical flow cytometry panel
3.6.Pricing ranges for technology

CHAPTER 4:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Asia-Pacific oncology molecular diagnostics market, by application

4.2.Colorectal cancer

4.2.1.Asia-Pacific oncology molecular diagnostics market, by technology for colorectal cancer
4.2.2.Colorectal oncology molecular diagnostics market, by PCR-based technology
4.2.3.Colorectal oncology molecular diagnostics market, by NGS based technology
4.2.4.Colorectal oncology molecular diagnostics market, by flow cytometry based technology
4.2.5.Colorectal oncology molecular diagnostics market, by FISH based technology
4.2.6.Colorectal oncology molecular diagnostics market, by CISH based technology
4.2.7.Colorectal oncology molecular diagnostics market, by others based technology

4.3.Hematological cancer

4.3.1.Market size and forecast
4.3.2.Hematological oncology molecular diagnostics market, by PCR-based technology
4.3.3.Hematological oncology molecular diagnostics market, by NGS based technology
4.3.4.Hematological oncology molecular diagnostics market, by flow cytometry based technology
4.3.5.Hematological oncology molecular diagnostics market, by FISH based technology
4.3.6.Hematological oncology molecular diagnostics market, by CISH based technology
4.3.7.Hematological oncology molecular diagnostics market, by others based technology

4.4.Breast cancer

4.4.1.Market size and forecast
4.4.2.Breast oncology molecular diagnostics market, by PCR-based technology
4.4.3.Breast oncology molecular diagnostics market, by NGS based technology
4.4.4.Breast oncology molecular diagnostics market, by flow cytometry based technology
4.4.5.Breast oncology molecular diagnostics market, by FISH based technology
4.4.6.Breast oncology molecular diagnostics market, by CISH based technology
4.4.7.Breast oncology molecular diagnostics market, by others based technology

4.5.Lung cancer

4.5.1.Market size and forecast
4.5.2.Lung oncology molecular diagnostics market, by PCR-based technology
4.5.3.Lung oncology molecular diagnostics market, by NGS based technology
4.5.4.Lung oncology molecular diagnostics market, by flow cytometry based technology
4.5.5.Lung oncology molecular diagnostics market, by FISH based technology
4.5.6.Lung oncology molecular diagnostics market, by CISH based technology
4.5.7.Lung oncology molecular diagnostics market, by others based technology

4.6.Other cancers

4.6.1.Market size and forecast
4.6.2.Others oncology molecular diagnostics market, by PCR-based technology
4.6.3.Others oncology molecular diagnostics market, by NGS based technology
4.6.4.Others oncology molecular diagnostics market, by flow cytometry based technology
4.6.5.Others oncology molecular diagnostics market, by FISH based technology
4.6.6.Others oncology molecular diagnostics market, by CISH based technology
4.6.7.Others oncology molecular diagnostics market, by others based technology

CHAPTER 5:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market size and forecast

5.3.Reference laboratories

5.3.1.Market size and forecast

5.4.Others

5.4.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

6.1.Overview

6.1.1.Key market trends and opportunities
6.1.2.Asia-Pacific Oncology Molecular Diagnostics market, by country

6.2.Australia

6.2.1.Australia oncology molecular diagnostics market, by application
6.2.2.Australia oncology molecular diagnostics market, by end user
6.2.3.Market share analysis of top players, 2018

6.3.Vietnam

6.3.1.Vietnam oncology molecular diagnostics market, by application
6.3.2.Vietnam oncology molecular diagnostics market, by end user
6.3.3.Market share analysis of top players, 2018

6.4.Thailand

6.4.1.Thailand oncology molecular diagnostics market, by application
6.4.2.Thailand oncology molecular diagnostics market, by end user
6.4.3.Market share analysis of top players, 2018

6.5.Philippines

6.5.1.Philippines oncology molecular diagnostics market, by application
6.5.2.Philippines oncology molecular diagnostics market, by end user
6.5.3.Market share analysis of top players, 2018

6.6.Rest of Asia-Pacific

6.6.1.Rest of Asia-Pacific oncology molecular diagnostics market, by application
6.6.2.Rest of Asia-Pacific oncology molecular diagnostics market, by end user

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.bioMerieux SA

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments

7.3.Qiagen N.V.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.F. Hoffmann-La Roche Ltd

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments

7.5.Siemens Healthineers

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.Danaher (Cepheid)

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.Diasorin SPA

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Business performance
7.7.5.Key strategic moves and developments

7.8.Illumina Inc.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.Agilent Technologies Inc.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.Sysmex Corporation

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments